Stoke Therapeutics
Price & Volume
Stats
See more52W Range | $5.35-$38.69 |
Market Cap | $1.8B |
Shares Short | 9M |
Financials
See moreRevenue (12 Mos) | $205.6M |
Revenue Growth (YoY) | 117.2% |
Gross Profit (12 Mos) | $205.6M |
Diluted EPS | $0.68 |
News
See moreYahoo Finance • last month
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Yahoo Finance • last month
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
Yahoo Finance • 2 months ago
A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results
About
CEO | Mr. Ian F. Smith A.C.A., C.P.A. |
Address | 45 Wiggins Avenue, Bedford, MA, United States, 01730 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 128 |
